Eton Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Eton Pharmaceuticals (Nasdaq: ETON) announced that CEO Sean Brynjelsen will present at the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Eton Pharmaceuticals (Nasdaq: ETON) announced that CEO Sean Brynjelsen will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 14, 2022, at 1:30 PM ET. The presentation will be available via webcast on the company's investor relations website. Eton focuses on developing treatments for rare diseases and currently markets products like ALKINDI SPRINKLE® and Carglumic Acid tablets. The company has additional rare disease products in development and is entitled to milestone payments or royalties on several products.
Details
News Market Reaction – ETON
The recorded move for ETON in the trading session of this news was -0.88%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DEER PARK, Ill., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that Sean Brynjelsen, Chief Executive Officer, will present at the H.C. Wainwright 24th Annual Global Investment Conference as follows:
| Date: | Wednesday, September 14, 2022 |
| Time: | 1:30PM ET |
| Webcast: | Click Here |
The webcast will be accessible via the Company’s website at https://ir.etonpharma.com/ the Investors section under Events and Presentations.
Eton will be participating in 1x1 meetings, which can be requested via H.C. Wainwright.
About Eton Pharmaceuticals
Eton Pharmaceuticals, Inc. is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently commercializes ALKINDI SPRINKLE® and Carglumic Acid tablets and has two additional rare disease products under development, dehydrated alcohol injection and the ZENEO® hydrocortisone autoinjector. In addition, the Company is entitled to receive milestone payments or royalties on seven different products.
Investor Relations:
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
Source: Eton Pharmaceuticals, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.